Literature DB >> 21841824

Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.

J Xu1, B Wang, Y Xu, L Sun, W Tian, D Shukla, R Barod, J Grillari, R Grillari-Voglauer, P H Maxwell, M A Esteban.   

Abstract

Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene underlies the majority of sporadic clear cell renal cell carcinomas (CCRCCs) and is also responsible for the hereditary VHL cancer syndrome. VHL loss of function results in constitutive stabilization of hypoxia-inducible factors (HIF-1α and HIF-2α) due to insufficient proteolysis in the presence of oxygen. This activates multiple genes relevant to tumorigenesis, allowing cells to acquire further mutations and undergo malignant transformation. However, the specific role of each HIF-α subunit in CCRCC tumorigenesis is not yet well understood. The current paradigm supports that in the first stages of CCRCC formation the stabilization of HIF-1α is dominant and this limits proliferation, but later on HIF-2α increases and this induces a more aggressive cell behavior. Understanding how this transition happens is highly relevant, as it may provide novel ways to treat these cancers. Here, we show that VHL inactivation in CCRCC cells results in HIF-1α/2α-dependent downregulation of HIF-1α mRNA through direct binding of either subunit to a reverse hypoxia-response element in the HIF-1α proximal promoter. This binding activates a series of repressive histone modification marks including histone 3 lysine 27 trimethylation (H3K27me3) to make the changes stable, and if overturned reduces CCRCC cell proliferation due to excessive HIF-1α expression level. Our findings thus help understand how HIF-α subunits influence each other and also reinforce the idea that epigenetic mechanisms are a key step of CCRCC progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841824     DOI: 10.1038/onc.2011.305

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Vulnerability of HIF1α and HIF2α to damage by proteotoxic stressors.

Authors:  Lauren M Meyers; Casey Krawic; Michal W Luczak; Anatoly Zhitkovich
Journal:  Toxicol Appl Pharmacol       Date:  2022-04-30       Impact factor: 4.460

Review 2.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

3.  HIF-2α in Resting Macrophages Tempers Mitochondrial Reactive Oxygen Species To Selectively Repress MARCO-Dependent Phagocytosis.

Authors:  Shirley Dehn; Matthew DeBerge; Xin-Yi Yeap; Laurent Yvan-Charvet; Deyu Fang; Holger K Eltzschig; Stephen D Miller; Edward B Thorp
Journal:  J Immunol       Date:  2016-09-26       Impact factor: 5.422

4.  HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts.

Authors:  J Ferdin; N Nishida; X Wu; M S Nicoloso; M Y Shah; C Devlin; H Ling; M Shimizu; K Kumar; M A Cortez; M Ferracin; Y Bi; D Yang; B Czerniak; W Zhang; T D Schmittgen; M P Voorhoeve; M J Reginato; M Negrini; R V Davuluri; T Kunej; M Ivan; G A Calin
Journal:  Cell Death Differ       Date:  2013-09-13       Impact factor: 15.828

Review 5.  Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Authors:  Erwin G Van Meir; Binghe Wang; Sarah K Burroughs; Stefan Kaluz; Danzhu Wang; Ke Wang
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

6.  The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity.

Authors:  Weihua Tian; Yu Wang; Yan Xu; Xiangpeng Guo; Bo Wang; Li Sun; Longqi Liu; Fenggong Cui; Qiang Zhuang; Xichen Bao; Gunnar Schley; Tung-Liang Chung; Andrew L Laslett; Carsten Willam; Baoming Qin; Patrick H Maxwell; Miguel A Esteban
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

7.  Epigenetic regulation of CD34 and HIF1A expression during the differentiation of human mast cells.

Authors:  Aurelia Walczak-Drzewiecka; Anna Salkowska; Marcin Ratajewski; Jaroslaw Dastych
Journal:  Immunogenetics       Date:  2013-03-26       Impact factor: 2.846

Review 8.  Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses.

Authors:  Joanna Obacz; Silvia Pastorekova; Borek Vojtesek; Roman Hrstka
Journal:  Mol Cancer       Date:  2013-08-14       Impact factor: 27.401

9.  PIWIL2 induces c-Myc expression by interacting with NME2 and regulates c-Myc-mediated tumor cell proliferation.

Authors:  Youlin Yao; Chao Li; Xiaoyan Zhou; Yu Zhang; Yilu Lu; Jianhui Chen; Xulei Zheng; Dachang Tao; Yunqiang Liu; Yongxin Ma
Journal:  Oncotarget       Date:  2014-09-30

10.  Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.

Authors:  David Vindrieux; Guillaume Devailly; Arnaud Augert; Benjamin Le Calvé; Mylène Ferrand; Pascal Pigny; Léa Payen; Gérard Lambeau; Michael Perrais; Sébastien Aubert; Hélène Simonnet; Robert Dante; David Bernard
Journal:  Oncotarget       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.